Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396867 | 0.80 | CHEK1 (0.48) | CHEK1CYP1A2CYP2A6NOS1CHEK2 | |
| SCHEMBL1396984 | 0.77 | PDPK1 (0.53) | CHEK1CYP1A2CYP2A6NOS1CHEK2 | |
| SCHEMBL2748752 | 0.77 | CHEK1 (0.46) | CHEK1CYP1A2CYP2A6NOS1CHEK2 | |
| SCHEMBL16168207 | 0.77 | CYP1A2 (0.53) | CHEK1CYP1A2CYP2A6NOS1CHEK2 | |
| SCHEMBL19663432 | 0.77 | KDM4E (0.47) | CHEK1CYP1A2CYP2A6CHEK2 | |
| SCHEMBL31496225 | 0.72 | CHEK1 (0.42) | CHEK1CYP1A2CYP2A6CHEK2L3MBTL1 | |
| SCHEMBL5668937 | 0.71 | CYP2A6 (0.62) | CHEK1CYP1A2CYP2A6NOS1AHR | |
| SCHEMBL29972350 | 0.71 | CYP2A6 (0.62) | CHEK1CYP1A2CYP2A6NOS1AHR | |
| SCHEMBL30930616 | 0.70 | CYP2A6 (0.54) | CHEK1CYP1A2CYP2A6L3MBTL1 | |
| SCHEMBL427159 | 0.70 | CYP2A6 (0.54) | CHEK1CYP1A2CYP2A6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4067347-A1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| CN-109476663-B | Pyrazolopyridine derivatives for the treatment of cancer | 基因泰克公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464286-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464270-A2 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205536-A2 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3204360-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | CHEK1 3227/4885CYP1A2 4114/4885CYP2A6 4197/4885 |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | CHEK1 3688/4885CYP1A2 4096/4885CYP2A6 3421/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CHEK1 3227/4885CYP1A2 4114/4885CYP2A6 4197/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | CHEK1 3258/4885CYP1A2 3649/4885CYP2A6 3623/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | CHEK1 3688/4885CYP1A2 4096/4885CYP2A6 3421/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | CHEK1 3258/4885CYP1A2 3649/4885CYP2A6 3623/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CHEK1 3227/4885CYP1A2 4114/4885CYP2A6 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.